跳至主要内容
临床试验/NCT01122524
NCT01122524已完成不适用

A Prospective, Multi-center Observational Study With Blinded, Nested Case:Control Analyses to Evaluate the Performance of the Verinata Health Prenatal Aneuploidy Diagnostic Test

Verinata Health, Inc.11 个研究点 分布在 1 个国家目标入组 10,000 人开始时间: 2010年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10,000
试验地点
11
主要终点
Classification of fetal status as affected or not affected for Trisomy 21 based on Artemis Health Test on maternal blood.

研究概览

简要总结

The primary objective of this study is to determine the performance characteristics (sensitivity and specificity) of the Verinata Health Test to detect fetal Trisomy 21 (T21) compared to karyotype results obtained by amniocentesis or chorionic villus sampling (CVS).

Secondary objectives are to assess performance of the test to detect male gender (XY) and other less common aneuploidies (Trisomy 13 (T13), Trisomy 18 (T18), and Turner Syndrome (45, X)) compared to clinical fetal karyotype.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age 18 years or older
  • Clinically confirmed viable pregnancy at the time of enrollment
  • Clinically determined gestational age between 8 wks, 0 days and 22 wks, 0 days
  • Referred or planning to undergo CVS or amniocentesis procedure due to risk of fetal aneuploidy based on protocol-specified clinical indicators
  • Able to provide consent for participation using language appropriate forms and consent process

排除标准

  • Invasive prenatal procedure (amniocentesis or CVS) performed prior to enrollment

结局指标

主要结局

Classification of fetal status as affected or not affected for Trisomy 21 based on Artemis Health Test on maternal blood.

时间窗: 10 months

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验